Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

393 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Ugly Duckling Sign as a Major Factor of Efficiency in Melanoma Detection.
Gaudy-Marqueste C, Wazaefi Y, Bruneu Y, Triller R, Thomas L, Pellacani G, Malvehy J, Avril MF, Monestier S, Richard MA, Fertil B, Grob JJ. Gaudy-Marqueste C, et al. Among authors: avril mf. JAMA Dermatol. 2017 Apr 1;153(4):279-284. doi: 10.1001/jamadermatol.2016.5500. JAMA Dermatol. 2017. PMID: 28196213
Management of adult patients with cutaneous melanoma without distant metastasis. 2005 update of the French Standards, Options and Recommendations guidelines. Summary report.
Saiag P, Bosquet L, Guillot B, Verola O, Avril MF, Bailly C, Cupissol D, Dalac S, Danino A, Dréno B, Grob JJ, Leccia MT, Renaud-Vilmer C, Négrier S; Société Française de Dermatologie. Saiag P, et al. Among authors: avril mf. Eur J Dermatol. 2007 Jul-Aug;17(4):325-31. doi: 10.1684/ejd.2007.0209. Epub 2007 Jun 1. Eur J Dermatol. 2007. PMID: 17540641 No abstract available.
Evidence of a limited intra-individual diversity of nevi: intuitive perception of dominant clusters is a crucial step in the analysis of nevi by dermatologists.
Wazaefi Y, Gaudy-Marqueste C, Avril MF, Malvehy J, Pellacani G, Thomas L, Triller R, Bruneu Y, Monestier S, Richard MA, Fertil B, Grob JJ. Wazaefi Y, et al. Among authors: avril mf. J Invest Dermatol. 2013 Oct;133(10):2355-2361. doi: 10.1038/jid.2013.183. Epub 2013 Apr 17. J Invest Dermatol. 2013. PMID: 23594596 Free article.
The kinetics of the visible growth of a primary melanoma reflects the tumor aggressiveness and is an independent prognostic marker: a prospective study.
Grob JJ, Richard MA, Gouvernet J, Avril MF, Delaunay M, Wolkenstein P, Souteyrand P, Bonerandi JJ, Machet L, Guillaume JC, Chevrant-Breton J, Vilmer C, Aubin F, Guillot B, Beylot-Barry M, Lok C, Raison-Peyron N, Chemaly P. Grob JJ, et al. Among authors: avril mf. Int J Cancer. 2002 Nov 1;102(1):34-8. doi: 10.1002/ijc.10660. Int J Cancer. 2002. PMID: 12353231
STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.
Delyon J, Chevret S, Jouary T, Dalac S, Dalle S, Guillot B, Arnault JP, Avril MF, Bedane C, Bens G, Pham-Ledard A, Mansard S, Grange F, Machet L, Meyer N, Legoupil D, Saiag P, Idir Z, Renault V, Deleuze JF, Hindie E, Battistella M, Dumaz N, Mourah S, Lebbe C; GCC (French Group of Skin Cancer). Delyon J, et al. Among authors: avril mf. J Invest Dermatol. 2018 Jan;138(1):58-67. doi: 10.1016/j.jid.2017.07.839. Epub 2017 Aug 24. J Invest Dermatol. 2018. PMID: 28843487 Free article. Clinical Trial.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial.
Bottomley A, Coens C, Mierzynska J, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Puig S, Ascierto PA, Larkin J, Lorigan PC, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C, Eggermont AMM; EORTC Melanoma Group. Bottomley A, et al. Lancet Oncol. 2021 May;22(5):655-664. doi: 10.1016/S1470-2045(21)00081-4. Epub 2021 Apr 12. Lancet Oncol. 2021. PMID: 33857414 Clinical Trial.
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial.
Eggermont AMM, Blank CU, Mandalà M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C; EORTC Melanoma Group. Eggermont AMM, et al. Lancet Oncol. 2021 May;22(5):643-654. doi: 10.1016/S1470-2045(21)00065-6. Epub 2021 Apr 12. Lancet Oncol. 2021. PMID: 33857412 Clinical Trial.
[Clinical practice guideline: 2005 update of recommendations for the management of patients with cutaneous melanoma without distant metastases (summary report)].
Négrier S, Saiag P, Guillot B, Verola O, Avril MF, Bailly C, Cupissol D, Dalac S, Danino A, Dreno B, Grob JJ, Leccia MT, Renaud-Vilmer C, Bosquet L; Standards, Options and Recommendations; Société Française de Dermatologie; Fédération Nationale des Centres de Lutte contre le Cancer; Institut National du Cancer; Ligue Nationale contre le Cancer; Fédération Hospitalière de France; Fédération Nationale de Cancerologie des CHRU; Fédération Francaise de Cancérologie. Négrier S, et al. Among authors: avril mf. Bull Cancer. 2006 Apr;93(4):371-84. Bull Cancer. 2006. PMID: 16714227 Free article. French.
Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases.
Grange F, Beylot-Barry M, Courville P, Maubec E, Bagot M, Vergier B, Souteyrand P, Machet L, Dalac S, Esteve E, Templier I, Delaporte E, Avril MF, Robert C, Dalle S, Laroche L, Delaunay M, Joly P, Wechsler J, Petrella T. Grange F, et al. Among authors: avril mf. Arch Dermatol. 2007 Sep;143(9):1144-50. doi: 10.1001/archderm.143.9.1144. Arch Dermatol. 2007. PMID: 17875875
393 results